**REGISTRATION IS NOW CLOSED.**

Glomerular disease is associated with morbidity and mortality in patients of all ages and is a common cause of end stage kidney disease. These include those that commonly present with nephrotic syndrome (minimal change disease, FSGS and membranous nephropathy), the nephrotic syndrome (vasculitis, lupus nephritis and IgA nephropathy), among others. Treatment often utilizes immunosuppressive regimens such as high dose corticosteroids, alkylating agents, calcineurin inhibitors, biologics and antimetabolites, which are associated with significant side effects and morbidity. Thus, glomerular diseases present a difficult and unique challenge to both patients and nephrologists and are associated with high treatment costs and historically, have had poor renal outcomes. There have been significant recent advances in the field in both the diagnosis and treatment of glomerular diseases, and the current guidelines for managing glomerular disease require updating. Therefore it is important for physicians to stay current with these new approaches to managing glomerular diseases.

1. Update how recent and ongoing clinical trials may impact the treatment of IgA nephropathy
2. Review recent data on the treatment of lupus nephritis
3. Explain how recent randomized controlled trials in ANCA associated vasculitis are informing clinical management of this disease
4. Gain expertise in diagnosing and treating membranous nephropathy in 2020
5. Develop comfort and competency in the use of serum anti PLA2R antibody testing in patients with membranous nephropathy
6. Review how recent genetic studies may impact the diagnosis and treatment of patients with glomerular disease

In support of improving patient care, Penn Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit
Penn Medicine designates this live activity for a maximum of 7.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Friday, September 11, 2020